Question 1

When should I consider clonidine or guanfacine for an anxious patient?

Accepted Answer

Alpha-2 agonists (clonidine, guanfacine) reduce anxiety by binding presynaptic alpha-2A receptors on locus coeruleus neurons, suppressing noradrenergic outflow and sympathetic tone. Guanfacine is 15-20x more selective for alpha-2A than clonidine, resulting in less sedation and hypotension. A 2017 pediatric trial (GXR, N=62, ages 6-17) showed 54.2% CGI-I responders versus 31.6% placebo as a secondary outcome, but did NOT achieve primary endpoints (PARS, SCARED). These agents are NOT first-line anxiolytics. Advantage over stimulants exists in ADHD-anxiety comorbidity (14-62% of anxious children). Clonidine carries rebound hypertension risk on abrupt discontinuation. Guanfacine dosing: start 1mg, titrate 1mg/week, max 4mg (ages 6-12) or 7mg (ages 13-17).

Question 2

How do alpha-2 agonists reduce anxiety through locus ceruleus modulation?

Accepted Answer

Alpha-2 agonists (clonidine, guanfacine) reduce anxiety by binding presynaptic alpha-2A receptors on locus coeruleus neurons, suppressing noradrenergic outflow and sympathetic tone. Guanfacine is 15-20x more selective for alpha-2A than clonidine, resulting in less sedation and hypotension. A 2017 pediatric trial (GXR, N=62, ages 6-17) showed 54.2% CGI-I responders versus 31.6% placebo as a secondary outcome, but did NOT achieve primary endpoints (PARS, SCARED). These agents are NOT first-line anxiolytics. Advantage over stimulants exists in ADHD-anxiety comorbidity (14-62% of anxious children). Clonidine carries rebound hypertension risk on abrupt discontinuation. Guanfacine dosing: start 1mg, titrate 1mg/week, max 4mg (ages 6-12) or 7mg (ages 13-17).

Question 3

Is guanfacine useful for ADHD-anxiety comorbidity in children?

Accepted Answer

Alpha-2 agonists (clonidine, guanfacine) reduce anxiety by binding presynaptic alpha-2A receptors on locus coeruleus neurons, suppressing noradrenergic outflow and sympathetic tone. Guanfacine is 15-20x more selective for alpha-2A than clonidine, resulting in less sedation and hypotension. A 2017 pediatric trial (GXR, N=62, ages 6-17) showed 54.2% CGI-I responders versus 31.6% placebo as a secondary outcome, but did NOT achieve primary endpoints (PARS, SCARED). These agents are NOT first-line anxiolytics. Advantage over stimulants exists in ADHD-anxiety comorbidity (14-62% of anxious children). Clonidine carries rebound hypertension risk on abrupt discontinuation. Guanfacine dosing: start 1mg, titrate 1mg/week, max 4mg (ages 6-12) or 7mg (ages 13-17).

Question 4

What are the hypotension and sedation risks?

Accepted Answer

Alpha-2 agonists (clonidine, guanfacine) reduce anxiety by binding presynaptic alpha-2A receptors on locus coeruleus neurons, suppressing noradrenergic outflow and sympathetic tone. Guanfacine is 15-20x more selective for alpha-2A than clonidine, resulting in less sedation and hypotension. A 2017 pediatric trial (GXR, N=62, ages 6-17) showed 54.2% CGI-I responders versus 31.6% placebo as a secondary outcome, but did NOT achieve primary endpoints (PARS, SCARED). These agents are NOT first-line anxiolytics. Advantage over stimulants exists in ADHD-anxiety comorbidity (14-62% of anxious children). Clonidine carries rebound hypertension risk on abrupt discontinuation. Guanfacine dosing: start 1mg, titrate 1mg/week, max 4mg (ages 6-12) or 7mg (ages 13-17).

PsychHQ

Alpha-2 Agonists for Anxiety: Clonidine and Guanfacine in Clinical Practice